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Pediatric Lipid Screening Guidelines:
Information for Patients and Providers
Erin R. Pichiotino, MPH
UVM College of Medicine Class of 2017 (MSIII)
Rotation 3
Milton Family Practice
Project Mentors: Dr. Timothy Lishnak, Holly Van Winkle
The Problem
 Children and adolescents with abnormal lipid levels are at significant risk for 
becoming adults with dyslipidemia with an increased risk for early 
cardiovascular disease (CVD) 
 Early identification and control of dyslipidemia through child- and adulthood 
can substantially reduce clinical CVD risk. Preliminary evidence of children 
with heterozygous familial hypocholesteremia shows reduced subclinical 
evidence of atherosclerosis with earlier treatment (Grade B) 
 Evidence has demonstrated that using family history as a primary factor to 
identify children for screening would miss 30-60% of children with inherited 
dyslipidemias (including 50% of those with familial hypocholesteremia) 
 Current medical organizations have incongruent guidelines and 
recommendations for pediatric lipid screening that are based on expert 
opinion only:
 Bright Futures/American Academy of Pediatrics recommends universal 
screening for children ages 9-11 and again at 17-21
 USPSTF concludes the evidence is insufficient to recommend for or 
against routine screening for lipid disorders in infants, children, 
adolescents, or young adults up to age 20. (Grade I) 
 Current recommended screening strategies have low adherence rates by 
pediatric health care providers. One study showed only 27.2% overall rate of 
lipid screening at ages 9-11 (56% for high-risk children)
Cost Considerations
 In the U.S today, 1 in 4 deaths are caused by heart disease and 1 in 20 
deaths are caused by stroke
 Heart disease and stroke account for more than $312.6 billion in direct 
health care expenditures and lost productivity, and a projected $444 billion 
in future costs. 
 A Fasting Lipid Panel (FLP) at UVMMC is $28.67 for the venipuncture and 
$78.63 for the panel, totaling $107.30 per screening of out of pocket costs 
(if no insurance coverage)
 No report is available for total # of pediatric patients by age cohort at 
Milton Family Practice, but roughly 10-12% of Family Medicine patients are 
under the age of 18 and MFP has roughly 2000 patients. 
 Thus, an estimated 200-240 patients are under the age of 18 at MFP
 Total estimated cost for two screenings per patient = $42,920 - $51,504 
for venipuncture and results alone
 There is considerable potential for psychological stress for venipuncture 
alone in patients and their families. Additional psychological stressors exist 
in patients/families not knowing the indication for the test, how to 
interpret the test, or how to cope with the potential treatment and 
management of the results.
Community Perspective
COLLECTED VIA
 Contacting experts in the following departments: Family Medicine, Pediatrics,
Pediatric Cardiology, Pediatric Gastroenterology
 Interviewing Dr. Kimberly Hageman (MFP, VCHIP Fit & Healthy Vermonters 
Toolkit Development Team, Pilot Tester)
 Interviewing Dr. Anne Morris (MFP)
 Interviewing Holly Van Winkle  (Practice Supervisor, MFP)
 Communicating with PRISM information services in regards to SmartPhrases, 
Reporting, and Flowsheet capabilities
 Creating 6-question survey distributed to MFP providers to gain perspective 
FINDINGS
 Only 25% (2) providers at MFP “Agreed” that they were comfortable applying 
the pediatric lipid screening guidelines
 75% (6) chose the 9-11yo and only 50.0% (4) chose ages 17-21 for the correct 
age groups to be universally screened.  37.51% (3) chose the incorrect age 
group of age 12-16yo
 Family Medicine providers feel there is limited evidence for the 
treatment/management for hyperlipidemia in children
 For practical reasons (lack of evidence, unclear and conflicting guidelines, lack 
of time to educate patients and families, difficulty obtaining venopuncture in 
children), providers report “going against the guidelines”
 Reporting and flowsheets using EHR have limited flexibility and functionality to 
run specific inquiries. Building these functionalities takes weeks-months and 




 “I do not think it makes sense. I am not going to 
prescribe a statin drug to an adolescent. We should 
be able to have frank discussions about obesity, diet, 
and exercise, without lab work.”
 “It would be nice to tie it to services that assist 
children and families to make effective lifestyle 
changes.”
 “Education is needed on this topic.”
 “…would love more information to help guide my 
practice.”
 “no clear evidence to support this, only expert panel 
recs, small number of kids in practice and so very 
small % kids who would have true significant 
dyslipidemias requiring more aggressive management 
than routine rec diet and exercise”
 “I don't know the screening guidelines”
 “Have not seen a large number of patients who 
qualify, will likely screen more in the future.”
Methodology
 Researched and categorized information on pediatric lipid 
screening guidelines
 Created survey using SurveyMonkey to collect information 
on Milton Family Practice (MFP) provider’s knowledge and 
perspectives of the guidelines
 Ran PRISM report exploring # of patients 9-11yo without 
lipid results at MFP (No report available for 17-21yo)
 Developed SmartPhrase in Epic to help providers know 1) 
who to screen 2)when to screen and 3)how to manage 
results
 Circulated survey results, report results, and 
SmartPhrases to providers and staff at MFP
Recommended Pediatric 
Lipid and Lipoprotein Cutpoints
Goal Borderline High+ 
(Low for HDL)

































 Bright Futures/American Academy of Pediatrics 
recommends universal screening for children ages 9-11 and 
again at 17-21
 USPSTF concludes the evidence is insufficient to recommend 
for or against routine screening for lipid disorders in infants, 




 See survey results under “Community Perspective” 
PRISM REPORT
 Currently at MFP, there are 111 patients ages 9-11 who 
have NOT been screened for lipids per the guidelines: 
[9yo (n=25); 10yo (n=47); 11yo (n=39)]
 At MFP 36.23% of children are overweight/obese 
(no age specific data available)
 ALL Family Medicine Departments in the UVMMC 
Network
 2-5yo = 463 (19%)
 6-11yo = 667 (28%)
 12-17yo = 969 (40%)
 18-21yo=316 (13%) 
 No report available for patients ages 17-21
SMARTTEXT
 SmartText with Flowsheet for the Universal Screening 
Guidelines for Ages 9-11 and for 17-21 currently 
available in PRISM as [pedslipidgoals] (next slide)
Results, cont.
SMARTTEXT
 Developed from Bright Futures/AAP guidelines for universal pediatric 
lipid screening as a quick way for providers to assess results and 
communicate the appropriate management next steps.
Evaluation
EFFECTIVENESS
 Based on survey results, there is ambiguity in knowing the guidelines and 
the application of the guidelines in clinical practice
 Evaluation could be done in conjunction with the VCHIP Obesity Work with 
Pediatricians, and/or by specific family practices to monitor the 
implementation of the guidelines and the use of the SmartPhrase
 From the survey, 37.5% Strongly Agreed and 62.5% Agreed that “A PRISM 
screening tool for who/when to screen pediatric patients and for how to 
interpret results would help provide quality health care”
 Questions should address what other practices, specifically in pediatrics, 
are doing in regards to Pediatric Lipid Screening, what resources are 
currently available, and how providers implement and communicate the 
guidelines with patients and their families
LIMITATIONS
 Universal pediatric lipid screening is based on expert opinion, not on 
randomized control trials or observational a studies exploring the benefits 
and utility of the practice
 Family Medicine Practices generally follow USPSTF guidelines, not Bright 
Futures/AAP guidelines, and for pediatric lipid screening, there are differing 
guidelines
 Inability to interview experts in pediatric cardiology and gastroenterology, 
who manage and consult for pediatric lipids. Input on what is currently 
being done in pediatric clinics could help guide practice in Family Medicine
 Inability to develop reporting and flowsheets in PRISM without consultation 
and financing support through information services
 Implementation ultimately up to providers, unless mandated by practice
Recommendations
EDUCATION
 Distribute survey to all UVMMC Family Practice providers
 Create a curriculum for Family Medicine provider’s on the guidelines and 
recommendations for Universal Pediatric Lipid Screening including reports and 
SmartText, building off presentation by Dr. Hageman’s pediatric 
obesity/VCHIP work
 Implement and distribute biannual reports on universal pediatric lipid 
screening by provider to monitor adherence
REPORTING
 Create Report for “Lipid Screening – PC – Patients 17-21 Never Had (My Dept)” 
in PRISM to identify patients to be screened
 Consider including lipid screening to Health Maintenance tab for all 9-11yo 
and 17-21yo within the FM Department
 Consider including lipid screening as part of the VCHIP Population based 
reports that are working to get children in every 24 months for a Well Child 
Check up. 
IMPLEMENTATOIN
 Consider including lipids as a Point-of-Care Testing (POCT) to increase 
likelihood that the patient and provider will receive results and have the 
opportunity to discuss the results and if applicable, act on immediate clinical 
management decisions
 Consider converting SmartPhrase to SmartSet or Pathway/Flowsheet to 
improve provider adherence to the guidelines 
 Monitor how often/who is using the SmartPhrase in PRISM
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